Jointown Pharmaceutical Group (600998) Q4 2025 earnings summary

Executive summary

• Achieved record annual revenue of ¥161.39 billion, up 6.31% year-over-year, outpacing industry growth.

• Operating cash flow improved 11.62% to ¥3.44 billion; adjusted net profit (excluding credit impairment) rose 9.13% year-over-year.

• Completed strategic acquisition of Aoyuan Beauty Valley, expanding into medical aesthetics.

• Upgraded credit rating to AAA, the only private AAA-rated company in the sector, reducing financing costs.

• Maintained robust corporate governance, with six consecutive years of top-tier information disclosure ratings.

Financial highlights

• Revenue: ¥161.39 billion, up 6.31% year-over-year.

• Net profit attributable to shareholders: ¥2.25 billion, down 10.07% year-over-year due to increased credit impairment and lower non-recurring gains.

• Adjusted net profit (excluding credit impairment): ¥1.98 billion, up 9.13% year-over-year.

• Operating cash flow: ¥3.44 billion, up 11.62% year-over-year.

• Gross margin: 7.75%; basic EPS: ¥0.44.

• Proposed cash dividend: ¥0.20 per share, total payout ¥997 million, 44.23% payout ratio.

Outlook and guidance

• Launched new three-year “Four New, Two Transformations” strategy (2026–2028): new products, new retail, new medical, new services, digitalization, capitalization.

• Targeting over 45,000 retail outlets and 10,000 clinic alliances within three years.

• Focus on AI-driven digital transformation, supply chain innovation, and capital market initiatives.